Provectus Biopharmaceuticals, Inc. (PVCT: null) | Provectus

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Provectus Biopharmaceuticals, Inc. (PVCT: null) | Provectus Biopharmaceuticals Alert - National Securities Law Firm Encourages Shareholders With Losses In Excess Of $100,000 To Contact Law Firm Before Lead Plaintiff Deadline Provectus Biopharmaceuticals Alert - National Securities Law Firm Encourages Shareholders With Losses In Excess Of $100,000 To Contact Law Firm Before Lead Plaintiff Deadline

Provectus Biopharmaceuticals Alert - National Securities Law Firm Encourages Shareholders With Losses In Excess Of $100,000 To Contact Law Firm Before Lead Plaintiff Deadline

PR Newswire

NEW YORK , May 28, 2014 /PRNewswire/ -- Tripp Levy PLLC, a leading national securities law firm, announced that a class action has been commenced in the United States District Court for the Middle District of Tennessee on behalf of purchasers of Provectus Biopharmaceuticals, Inc. ("Provectus") (NYSEMKT:PVCT) publicly traded securities during the period between December 17, 2013 and May 22, 2014 (the "Class Period").

If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2014 . If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Tripp Levy PLLC via e-mail at contact@tripplevy.com or visit our website at www.tripplevy.com . Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

The complaint charges Provectus and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Provectus, formerly Provectus Pharmaceuticals, Inc., is a development-stage pharmaceutical company that is engaged in developing pharmaceuticals for oncology and dermatology indications, including PV-10, which is intended for the treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer.

The complaint alleges that throughout the Class Period, defendants violated the federal securities laws by disseminating false and misleading statements to the investing public regarding the prospects for PV-10. As a result of defendants' false statements, Provectus stock traded at artificially inflated prices during the Class Period, reaching a high of $5.22 per share on January 22, 2014 .

On January 23, 2014 , Adam Feuerstein published an article on TheStreet.com alleging that Provectus management had misled investors about the prospects for PV-10, questioning why Provectus had not yet started its promised Phase 3 randomized controlled trial of PV-10 and speculating that PV-10 may be obsolete in light of new skin cancer drugs being developed. On this news, Provectus's stock price fell $3.35 per share to close at $1.87 per share on January 23, 2014 , a decline of nearly 64% on volume of 30.5 million shares. On May 20, 2014 , Feuerstein noted in an article published on TheStreet.com that on its website, Provectus had initially described its PV-10 drug as a "breakthrough" drug for skin cancer, but had later amended its description to "investigational." Subsequently, on May 21, 2014 , an investment community blog on SeekingAlpha.com highlighted the failure of Provectus to commence a Phase 3 trial of PV-10 and alleged that the Company was tied to a stock promotion firm whose other stock recommendations had recently had trading in their stock halted by the SEC. On the same day, Provectus issued a press release refuting inaccuracies in the blog on SeekingAlpha.com . On this news, Provectus's stock price dropped $0.22 per share to close at $2.02 per share on May 22, 2014 , a one-day decline of nearly 10%, and on May 23, 2014 , trading in Provectus stock was halted at $2.02 per share.

Plaintiffs seek to recover damages on behalf of all purchasers of Provectus publicly traded securities during the Class Period (the "Class").  Tripp Levy PLLC is a leading national securities and shareholder rights law firm with offices across the country representing both individual and institutional shareholders and, along with its affiliates, has recovered billions of dollars for shareholders.   Tripp Levy PLLC is affiliated with Milberg LLP.  Attorney advertising.  Prior results do not indicate a similar outcome

Email: contact@tripplevy.com  

1-800-511-7037


 www.tripplevy.com

SOURCE Tripp Levy PLLC

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 562

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 284

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 419

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 220

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 494

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 378

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 437

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

CGI Elevates Its Cloud Solutions with AWS Premier Status

Updated Category News Views 210

CGI Achieves Amazon Web Services Premier Tier Status CGI (NYSE: GIB) has recently reached a significant milestone by being recognized as an Amazon Web Services (AWS) Premier Tier Services Partner. This distinction represents the highest level in the AWS Partner Network, showcasing CGI's dedication to providing top-notch IT and consulting services. With this status, CGI...

Continue Reading
Velo3D Stock Surge: Insider Moves and Contract Boost

Updated Category News Views 219

Velo3D Inc (NASDAQ:VELO) is on the rise, trading up 3.77% to $9.36 following buzz around insider transactions and a significant defense contract. The market's reaction points to investor enthusiasm, but is there substance behind the spike? Sharp Rebound After Recent Sell-Off: What’s Behind It? Just days ago, VELO shares took a nosedive despite the announcement of an...

Continue Reading
Empowering Lives: The Role of Genetic Screening in Cancer Prevention

Updated Category News Views 33

Empowering Lives Through Genetic Screening jscreen, a national non-profit public health initiative dedicated to preventing genetic diseases and cancer, is ramping up efforts to educate the public regarding the crucial benefits of proactive genetic screening. The organization is committed to ensuring accessibility and affordability of cancer genetic testing, offering...

Continue Reading
BigBear.ai Holdings Faces Investigation by National Law Firm

Updated Category News Views 279

Investigation Launched Against BigBear.ai Holdings Bragar Eagel & Squire, P.C., known for its commitment to representing shareholder rights, has announced an investigation into BigBear.ai Holdings, Inc. (BBAI). This inquiry is spurred by a class action lawsuit that raises serious allegations regarding the company's management and their adherence to fiduciary duties. The...

Continue Reading
BitMEX Unveils Exciting Trading Competition for Lunar New Year

Updated Category News Views 192

BitMEX Launches an Exciting Trading Competition for the Lunar New Year BitMEX, recognized as a pioneer in the crypto derivatives trading space, has announced its latest competition in celebration of the Lunar New Year. This competition, aptly named the 'Slither to Success Trading Competition,' has drawn interest from traders eager to seize the opportunity to win a share...

Continue Reading